...
首页> 外文期刊>The Journal of general physiology >Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents.
【24h】

Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents.

机译:ATP敏感的K +通道调节剂对囊性纤维化跨膜电导调节剂氯化物电流的影响。

获取原文
           

摘要

The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that is regulated by cAMP-dependent phosphorylation and by intracellular ATP. Intracellular ATP also regulates a class of K+ channels that have a distinct pharmacology: they are inhibited by sulfonylureas and activated by a novel class of drugs called K+ channel openers. In search of modulators of CFTR Cl- channels, we examined the effect of sulfonylureas and K+ channel openers on CFTR Cl- currents in cells expressing recombinant CFTR. The sulfonylureas, tolbutamide and glibenclamide, inhibited whole-cell CFTR Cl- currents at half-maximal concentrations of approximately 150 and 20 microM, respectively. Inhibition by both agents showed little voltage dependence and developed slowly; 90% inhibition occurred 3 min after adding 1 mM tolbutamide or 100 microM glibenclamide. The effect of tolbutamide was reversible, while that of glibenclamide was not. In contrast to their activating effect on K+ channels, the K+ channel openers, diazoxide, BRL 38227, and minoxidil sulfate inhibited CFTR Cl- currents. Half-maximal inhibition was observed at approximately 250 microM diazoxide, 50 microM BRL 38227, and 40 microM minoxidil sulfate. The rank order of potency for inhibition of CFTR Cl- currents was: glibenclamide BRL 38227 approximately equal to minoxidil sulfate tolbutamide diazoxide. Site-directed mutations of CFTR in the first membrane-spanning domain and second nucleotide-binding domain did not affect glibenclamide inhibition of CFTR Cl- currents. However, when part of the R domain was deleted, glibenclamide inhibition showed significant voltage dependence. These agents, especially glibenclamide, which was the most potent, may be of value in identifying CFTR Cl- channels. They or related analogues might also prove to be of value in treating diseases such as diarrhea, which may involve increased activity of the CFTR Cl- channel.
机译:囊性纤维化跨膜电导调节剂(CFTR)是一个c通道,由cAMP依赖性磷酸化和细胞内ATP调节。细胞内ATP还调节一类具有独特药理作用的K +通道:它们被磺酰脲类药物抑制并被一类称为K +通道开放剂的新型药物激活。为了寻找CFTR Cl-通道的调节剂,我们研究了磺酰脲类和K +通道开放剂对表达重组CFTR的细胞中CFTR Cl-电流的影响。磺酰脲类,甲苯磺丁酰胺和格列本脲在半最大浓度分别为约150和20 microM时抑制全细胞CFTR Cl-电流。两种试剂的抑制作用均显示出对电压的依赖性很小,并且发展缓慢。加入1 mM甲苯磺丁酰胺或100 microM格列本脲3分钟后,> 90%的抑制作用发生。甲苯磺丁酰胺的作用是可逆的,而格列本脲的作用却不可逆。与它们对K +通道的激活作用相反,K +通道开放剂,二氮嗪,BRL 38227和硫酸米诺地尔抑制CFTR Cl-电流。在约250 microM二叠氮,50 microM BRL 38227和40 microM米诺地尔硫酸盐中观察到一半最大抑制。抑制CFTR Cl电流的效力的等级顺序为:格列本脲甲苯磺丁酰胺>二氮嗪。 CFTR在第一个跨膜结构域和第二个核苷酸结合结构域中的定点突变不会影响格列本脲对CFTR Cl电流的抑制作用。但是,当删除部分R结构域时,格列本脲抑制表现出显着的电压依赖性。这些药物,尤其是最有效的格列本脲,可能对鉴定CFTR Cl-通道有价值。它们或相关类似物也可能被证明对治疗腹泻等疾病有价值,这些疾病可能涉及CFTR Cl通道活性的增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号